

Jul 2025



Contents


Macro	economy	Page 2
1.	Deflation To Last With Easing Sign	
2.	Frontloading Effect To Be Paid Back In 2H25	
3.	Divergence For Policy Support Impact On 2H25 Outlook	
4.	China Macro Outlook	
Marke	et Outlook	Page 6
1.	Market outlook	
2.	Earnings	
3.	Valuation	
4.	Liquidity	
Monitoring Points & Investment Theme		Page 10
1.	Property Market Transaction	
2.	Quarterly Investment Theme	



Quarterly Macro Highlight (1): Deflation To Last With Easing Sign

- GDP deflator contracted yoy in 2Q25, deflation for the 9th consecutive quarter.
- We judge that deflation should last at least until the end of 2026 due to insufficient demand.
- However, we do not expect deflation to deepen further, going forward. Daily steel prices showed a sign of PPI deflation to ease in 3Q25.

Continuous Deflation



(Source: CEIC, SMDAM) (As of Apr-Jun 2025)

Easing Steel Deflation




(Source: CEIC, SMDAM) (As of 24 Jul 2025)



Quarterly Macro Highlight (2): Export Frontloading To Be Paid Back In 2H25


- Despite of higher tariff imposed by US, China export momentum held up well so far.
- On seasonally adjusted basis, exports to US bottomed out in Jun reflecting decrease in tariff rate in May.
- However, exports to ASEAN started to show sign of slowdown in Jun due to negative backlash from frontloading exports.
- We think more payback shall happen going forward, on strong frontloading exports till Aug, end of 90 days grace period.

Export Momentum Remained Solid



Note: qqar based on seasonally adjusted basis (Source: CEIC, SMDAM) (As of Jun 2025)

Normalizing Exports to US




(Source: CEIC, SMDAM) (As of Jun 2025)

Quarterly Macro Highlight (3): Divergence For Policy Support Impact On 2H25 Outlook

- Industrial production growth accelerated in Jun led by high-tech sector. Steel production momentum continuously decelerated in Jun.
- Going forward, we think high-tech sector shall continue to lead the industrial production growth; while certain sectors may subject to policy headwind due to 'anti-involution' vow.
- Retail sales have outperformed in 1H25 due to strong policy support. However, we think momentum should decelerate in 2H25 partly due to negative backlash from frontloading trade-in program.

Solid Industrial Production Performance



Declining Consumption Momentum



(Source: CEIC, SMDAM) (As of Jun, 2025)

(Source: CEIC, WIND, SMDAM) (As of Jun, 2025)



China Macro Economy Outlook

- We expect real GDP growth momentum to decelerate in 2H25.
- We judge deflation to last beyond 2026 but not to deepen further.
- CNY should face some depreciation pressure under USD range-bound phase.

China Macro Economy Outlook

	2023	2024	2025	2026	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26	3Q26	4Q26
			(F)	(F)							(F)	(F)	(F)	(F)	(F)	(F)
Real GDP	5.2	5.0	4.8	4.6	5.3	4.7	4.6	5.4	5.4	5.2	4.7	4.3	4.5	4.6	4.6	4.7
consumption	8.3	3.9	3.8	3.7	NA											
investment	3.5	3.2	4.6	3.8	NA											
net exports (contribution)	-0.8	1.5	0.9	1.3	NA											
Nominal GDP	4.6	4.2	3.9	4.2	4.2	4.0	4.1	4.6	4.6	3.9	3.8	3.6	3.8	4.1	4.3	4.4
GDP deflator	-0.5	-0.7	-0.9	-0.5	-1.3	-0.6	-0.5	-0.7	-0.8	-1.2	-0.9	-0.7	-0.7	-0.5	-0.3	-0.3
industrial production	4.5	5.8	6.0	5.5	6.1	5.8	5.0	5.7	6.5	6.3	5.8	5.5	5.3	5.5	5.5	5.5
PPI inflation	-3.0	-2.2	-2.8	-0.9	-2.7	-1.6	-1.7	-2.6	-2.3	-3.3	-3.0	-2.5	-1.5	-0.8	-0.6	-0.5
CPI inflation	0.2	0.2	-0.1	0.1	0.0	0.3	0.5	0.2	-0.1	-0.1	-0.1	0.0	0.0	0.1	0.2	0.1
7D reverse repo rate	1.80	1.50	1.20	1.10	1.80	1.80	1.50	1.50	1.50	1.40	1.20	1.20	1.10	1.10	1.00	1.00
CNY/USD	7.10	7.30	7.20	7.30	7.22	7.27	7.02	7.30	7.26	7.16	7.18	7.20	7.20	7.25	7.25	7.30

2025	2026					
consensus						
4.7	4.2					
NA	NA					
NA	NA					
NA	NA					
NA	NA					
NA	NA					
5.0	4.5					
-2.5	-0.5					
0.2	1.0					
1.30	1.20					
7.15	7.10					
· ·						

(note) gothic figures for actual

yoy growth expect for next exports and interest rates

Consensus figures are based on Bloomberg on 24 Jul 2025.

(source) SMDAM, CEIC and Bloomberg

Outlook for China A-Share Equity Market (CSI 300)

Current CSI 300 valuation has moved to slightly above historical average level after rally triggered by better than expected 1H results in AI related Tech companies. Under our base case scenario, near term index upside is very limited as EPS has further downward revision pressure despite being moderate.



12 month forward EPS forecast for CSI300

Earnings Expectation had remained stable throughout last 12M. There was some upward revision driven by Consumer and IT sectors after interim profit alert in Jul 2025, but sustainability still needs monitoring.

CSI300 Outlook 12M Forward EPS




(yy/mm)

Earnings multiples* for CSI300

* Price-to-earnings ratio based on 12 month forward EPS

12 month forward PER stands at 13.3 times, which is above its Long Term Average. Our base case assumes it will be reasonable to stay around this level due to stimulus pivot and National Team support. Further sharp re-rating depends on potential EPS upward revision along with effects from stimulus policies starting to realize.


Price to Earnings ratio for CSI300



Monitoring Point: Property Market

Property Market remains one of the most important industries for Chinese Economy. In 2025 ytd, transaction showed weakening trend again despite of existing down payment reduction and Mortgage Rate Cut.

Daily New Home Transaction (7 Days Average)




(Source: Wind, SMDAM) (Date: As of 23rd Jul, 2025)

Quarterly Investment Theme: Innovative Drugs Opportunities

- Robust out-licensing activity of innovative drugs by Chinese developers has been a major driver of the year-to-date sector rally. In 1H25, there was a total of 50 documented out-licensing deals by Chinese developers with multinationals.
- Global data reported that Chinese out-licensing deals to the US only in 2024 amounted to US\$21.3bn, up 36% vs. 2023.

Strong Momentum on Chinese Innovative Drugs out-licensing

Exhibit 1: Cumulative upfront and total deal sizes of Chinese out-licensing deals in the biopharmaceutical sector in 1H25



Note: Above data is to the extent disclosed. Of 50 out-licensing deals in 1H2025, 34 companies disclosed upfront and/or total deal size. Source: Drug Times; Morgan Stanley Research.



General Disclaimer

This material is for general information purposes only without regard to any particular user's investment objectives or financial situation. It is educational in nature and should not be interpreted or constituted as an offer, solicitation or recommendation or advice to buy or sell securities or pursue any particular investment strategy or investment product in any jurisdiction or country, nor is it a commitment from Sumitomo Mitsui DS Asset Management Company, Limited or any of its subsidiaries ("SMDAM Group") to participate in any of the transactions mentioned herein. Any examples used are generic, hypothetical and for illustration purposes only. No representation or promise as to the performance of funds or the return on any investment is made. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, and are based on certain assumptions and current market conditions that are subject to change without prior notice.

The material is correct to the best of our knowledge at the date of issue and subject to change without notice. We do not guarantee its accuracy, completeness, fairness or timeliness, and make no representations or warranties, express or implied, as to the accuracy or completeness of the statements or any information contained therein and any liability for any error, inaccuracy or omission is expressly disclaimed. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. Nothing in this material constitutes accounting, legal, regulatory, tax or other advice.

It should be noted that investment involves risks, including the possible loss of the principal amount invested, and the value of your investment may rise or fall. Past performance and yields are not necessarily indicative of current or future results.

This material is issued by the following entities:

In Japan, by Sumitomo Mitsui DS Asset Management Company, Limited. It is for non-Japanese institutional investors only and is not intended to offer or solicit investments, provide investment advice or service, or to be considered as disclosure documents under the Financial Instruments and Exchange Law of Japan.

In the United Kingdom, by Sumitomo Mitsui DS Asset Management (UK) Limited. It constitutes a financial promotion for the purposes of the Financial Services and Markets Act 2000 (as amended) (FSMA) and the rules of the FCA in the United Kingdom, and is directed at professional clients as defined in the FCA Handbook of Rules and Guidance.

In Hong Kong, by Sumitomo Mitsui DS Asset Management (Hong Kong) Limited. The contents of this material has not been reviewed by the Securities and Futures Commission.

In Singapore, by Sumitomo Mitsui DS Asset Management (Singapore) Pte. Ltd. It is only for accredited investors and institutional investors as defined in the Securities and Futures Act 2001 ("SFA"). You may wish to seek advice from an independent professional and financial advice before investing in any investment, and if you choose not to seek such advice, you should consider carefully whether the investment is suitable for you.

General Terms

The intellectual property and all rights of the benchmarks/indices belong to the publisher and the authorized entities/individuals. The video itself or the contents of the video may not be copied, redistributed, reproduced or relied upon by any person, in whole or in part, without prior written approval from SMDAM Group. All rights, titles and interests in this material and any content contained herein are the exclusive properties of SMDAM Group, except as otherwise stated.

